BC Week In Review | Jan 9, 2012
Clinical News

C-Topical: SPA received

Lannett received an SPA from FDA for a double-blind, placebo-controlled Phase III trial to evaluate C-Topical in at least 500 patients. The company is developing the product under section 505(b)(2) of the Food, Drug and...
BioCentury | Jan 9, 2012

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
Items per page:
1 - 2 of 2